Skip to main content
Top
Published in: Supportive Care in Cancer 3/2006

01-03-2006 | Original Article

Complementary and alternative medicine use in breast cancer patients in Europe

Authors: Alexander Molassiotis, Julia A. Scott, Nora Kearney, Dorit Pud, Miriam Magri, Sarka Selvekerova, Ingrid Bruyns, Paz Fernadez-Ortega, Vassiliki Panteli, Anita Margulies, Gudbjorg Gudmundsdottir, Ljiljana Milovics, Gulten Ozden, Nurgun Platin, Elisabeth Patiraki

Published in: Supportive Care in Cancer | Issue 3/2006

Login to get access

Abstract

Complementary and alternative medicine (CAM) has gained popularity among cancer patients in the past years. For this study, CAM includes any group of health care systems, practices or products that are not considered to be part of conventional medicine at present (National Center for Complementary and Alternative Medicine). The present study assessed patterns of CAM use in breast cancer patients in Europe. The study used a descriptive cross-sectional design, and data were collected through a 27-item questionnaire. The sample, which was part of a larger study, consisted of 282 breast cancer patients from 11 countries in Europe. Among participants, 44.7% used CAM since their diagnosis of cancer. The most common therapies used included herbal medicine (46.4%) and medicinal teas, relaxation techniques, spiritual therapies, homeopathy and vitamins/minerals. Younger patients with higher education and who had received combination treatments for their cancer in the past were more likely to use CAM. High levels of satisfaction were reported, with only 6.5% of the women reporting no benefits from the CAM used. Main sources of information about CAM were mostly friends/family and the media. Findings suggested that a high proportion of breast cancer patients used CAM, which may have implications for the clinical management of these patients.
Literature
1.
go back to reference Ashikaga T, Bosompra K, O’Brien P, Nelson L (2002) Use of complimentary and alternative medicine in breast cancer patients: prevalence, patterns and communication with physicians. Support Care Cancer 10:542–548 Ashikaga T, Bosompra K, O’Brien P, Nelson L (2002) Use of complimentary and alternative medicine in breast cancer patients: prevalence, patterns and communication with physicians. Support Care Cancer 10:542–548
2.
go back to reference Boon H, Stewart M, Kennard MA, Gray R, Sawka C, Brown JB, McWilliam C, Gavin A, Baron RA, Aaron D, Haines-Kamka T (2000) Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 18:2515–2521PubMed Boon H, Stewart M, Kennard MA, Gray R, Sawka C, Brown JB, McWilliam C, Gavin A, Baron RA, Aaron D, Haines-Kamka T (2000) Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 18:2515–2521PubMed
3.
go back to reference Burstein HJ, Gelber S, Guadagnoli E, Weeks JC (1999) Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340:1733–1739CrossRefPubMed Burstein HJ, Gelber S, Guadagnoli E, Weeks JC (1999) Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340:1733–1739CrossRefPubMed
4.
go back to reference DiGianni LM, Garber JE, Winer EP (2002) Complementary and alternative medicine use among women with breast cancer. J Clin Oncol 20(18s):34s–38sPubMed DiGianni LM, Garber JE, Winer EP (2002) Complementary and alternative medicine use among women with breast cancer. J Clin Oncol 20(18s):34s–38sPubMed
5.
go back to reference Downer SM, Cody MM, McCluskey P, Wilson PD, Arnott SJ, Lister TA, Slevin ML (1994) Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ 309:86–89PubMed Downer SM, Cody MM, McCluskey P, Wilson PD, Arnott SJ, Lister TA, Slevin ML (1994) Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ 309:86–89PubMed
6.
go back to reference Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC (1998) Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 280:1569–1575CrossRefPubMed Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC (1998) Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 280:1569–1575CrossRefPubMed
7.
go back to reference Ernst E (2000) Possible interactions between synthetic and herbal medicinal products. Part I: a systematic review of the indirect evidence. Perfusion 13:4–6, 8 Ernst E (2000) Possible interactions between synthetic and herbal medicinal products. Part I: a systematic review of the indirect evidence. Perfusion 13:4–6, 8
9.
go back to reference Fisher P, Ward A (1994) Complementary medicine in Europe. BMJ 309:107–111PubMed Fisher P, Ward A (1994) Complementary medicine in Europe. BMJ 309:107–111PubMed
10.
go back to reference Ganz P, Desmond K, Leedham B et al (2000) Quality of life in long-term, disease free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 92:42–47CrossRefPubMed Ganz P, Desmond K, Leedham B et al (2000) Quality of life in long-term, disease free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 92:42–47CrossRefPubMed
11.
go back to reference Gertz MA, Bauer BA (2001) Caring (really) for patients who use alternative therapies for cancer. J Clin Oncol 19:4346–4349PubMed Gertz MA, Bauer BA (2001) Caring (really) for patients who use alternative therapies for cancer. J Clin Oncol 19:4346–4349PubMed
12.
go back to reference Gilbar O, Iron G, Goren A (2001) Adjustment to illness of cancer patients treated by complementary therapy along with conventional therapy. Patient Educ Couns 44:243–249CrossRefPubMed Gilbar O, Iron G, Goren A (2001) Adjustment to illness of cancer patients treated by complementary therapy along with conventional therapy. Patient Educ Couns 44:243–249CrossRefPubMed
13.
go back to reference Graham JG, Quinn ML, Fabricant DS, Farnsworth NR (2000) Plants used against cancer—an extension of the work of Jonathan Hartwell. J Ethnopharmacol 73:347–377CrossRefPubMed Graham JG, Quinn ML, Fabricant DS, Farnsworth NR (2000) Plants used against cancer—an extension of the work of Jonathan Hartwell. J Ethnopharmacol 73:347–377CrossRefPubMed
14.
go back to reference Gray RE, Fitch M, Goel V, Franssen E, Labrecque M (2003) Utilization of complementary/alternative services by women with breast cancer. J Health Soc Policy 16:75–84CrossRef Gray RE, Fitch M, Goel V, Franssen E, Labrecque M (2003) Utilization of complementary/alternative services by women with breast cancer. J Health Soc Policy 16:75–84CrossRef
15.
go back to reference Henderson JW, Donatelle RJ (2004) Complementary and alternative medicine use by women after completion of allopathic treatment for breast cancer. Altern Ther Health Med 10:52–57 Henderson JW, Donatelle RJ (2004) Complementary and alternative medicine use by women after completion of allopathic treatment for breast cancer. Altern Ther Health Med 10:52–57
16.
go back to reference Jacobson JS, Verret WJ (2001) Complementary and alternative therapy for breast cancer. The evidence so far. Cancer Pract 9:307–310CrossRefPubMed Jacobson JS, Verret WJ (2001) Complementary and alternative therapy for breast cancer. The evidence so far. Cancer Pract 9:307–310CrossRefPubMed
17.
go back to reference Kiefer D, Shah S, Gardiner P, Wechkin H (2001) Finding information on herbal therapy: a guide to useful sources for clinicians. Altern Ther Health Med 7:74–78PubMed Kiefer D, Shah S, Gardiner P, Wechkin H (2001) Finding information on herbal therapy: a guide to useful sources for clinicians. Altern Ther Health Med 7:74–78PubMed
18.
go back to reference Lee MM, Lin SS, Wrensch MR, Adler SR, Eisenberg D (2000) Alternative therapies used by women with breast cancer in four ethnic populations. J Natl Cancer Inst 92:42–47CrossRefPubMed Lee MM, Lin SS, Wrensch MR, Adler SR, Eisenberg D (2000) Alternative therapies used by women with breast cancer in four ethnic populations. J Natl Cancer Inst 92:42–47CrossRefPubMed
19.
go back to reference Lengacher CA, Bennett MP, Kip KE, Keller R, LaVance MS, Smith LS, Cox CE (2002) Frequency of use of complementary and alternative medicine in women with breast cancer. Oncol Nurs Forum 29:1445–1452PubMed Lengacher CA, Bennett MP, Kip KE, Keller R, LaVance MS, Smith LS, Cox CE (2002) Frequency of use of complementary and alternative medicine in women with breast cancer. Oncol Nurs Forum 29:1445–1452PubMed
20.
go back to reference Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics L, Bruyns I, Gudmundsdottir G, Hummerston S, Ahmad AM-A, Platin N, Kearney N, Patiraki E (2005) Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 16:655–663CrossRefPubMed Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics L, Bruyns I, Gudmundsdottir G, Hummerston S, Ahmad AM-A, Platin N, Kearney N, Patiraki E (2005) Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 16:655–663CrossRefPubMed
21.
go back to reference Morris KT, Johnson N, Homer L, Walts D (2000) A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg 179:407–411CrossRefPubMed Morris KT, Johnson N, Homer L, Walts D (2000) A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg 179:407–411CrossRefPubMed
22.
go back to reference Moschen R, Kemmler G, Schweigkofler H, Holzner B, Dunser M, Richter R, Fleischhacker WW, Sperner-Unterweger B (2001) Use of alternative/complementary therapy in breast cancer patients—a psychological perspective. Support Care Cancer 9:267–274CrossRefPubMed Moschen R, Kemmler G, Schweigkofler H, Holzner B, Dunser M, Richter R, Fleischhacker WW, Sperner-Unterweger B (2001) Use of alternative/complementary therapy in breast cancer patients—a psychological perspective. Support Care Cancer 9:267–274CrossRefPubMed
23.
go back to reference Rees RW, Feigel I, Vickers A, Zollman C, McGurk R, Smith C (2000) Prevalence of complementary therapy use by women with breast cancer: a population based survey. Eur J Cancer 36:1359–1364CrossRefPubMed Rees RW, Feigel I, Vickers A, Zollman C, McGurk R, Smith C (2000) Prevalence of complementary therapy use by women with breast cancer: a population based survey. Eur J Cancer 36:1359–1364CrossRefPubMed
24.
go back to reference Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505–2514PubMed Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505–2514PubMed
25.
go back to reference Ritvo P, Irvine J, Katz J, Matthew A, Sacamano MA, Shaw BF (1999) The patient’s motivation in seeking complementary therapies. Patient Educ Couns 38:161–165CrossRefPubMed Ritvo P, Irvine J, Katz J, Matthew A, Sacamano MA, Shaw BF (1999) The patient’s motivation in seeking complementary therapies. Patient Educ Couns 38:161–165CrossRefPubMed
26.
go back to reference Shen J, Andersen R, Albert PS, Wenger N, Glaspy J, Cole M, Shekelle P (2002) Use of complementary/alternative therapies by women with advanced-stage breast cancer. BMC Complement Altern Med 2:8CrossRefPubMed Shen J, Andersen R, Albert PS, Wenger N, Glaspy J, Cole M, Shekelle P (2002) Use of complementary/alternative therapies by women with advanced-stage breast cancer. BMC Complement Altern Med 2:8CrossRefPubMed
27.
go back to reference Shumay DM, Maskarinec G, Gotay CC, Heiby EM, Kakai H (2002) Determinants of the degree of complementary and alternative medicine use among patients with cancer. J Altern Complement Med 8:661–671CrossRefPubMed Shumay DM, Maskarinec G, Gotay CC, Heiby EM, Kakai H (2002) Determinants of the degree of complementary and alternative medicine use among patients with cancer. J Altern Complement Med 8:661–671CrossRefPubMed
28.
go back to reference Smith M, Boon HS (1999) Counseling cancer patients about herbal medicine. Patient Educ Couns 38:109–120CrossRefPubMed Smith M, Boon HS (1999) Counseling cancer patients about herbal medicine. Patient Educ Couns 38:109–120CrossRefPubMed
29.
go back to reference Swisher EM, Cohn DE, Goff BA, Parham J, Herzog TJ, Rader JS, Mutch DG (2002) Use of complementary and alternative medicine among women with gynaecologic cancers. Gynecol Oncol 84:363–367CrossRefPubMed Swisher EM, Cohn DE, Goff BA, Parham J, Herzog TJ, Rader JS, Mutch DG (2002) Use of complementary and alternative medicine among women with gynaecologic cancers. Gynecol Oncol 84:363–367CrossRefPubMed
30.
go back to reference VandeCreek L, Rogers E, Lester J (1998) Use of alternative therapies among breast cancer outpatients compared with the general population. Altern Ther Health Med 5:71–76 VandeCreek L, Rogers E, Lester J (1998) Use of alternative therapies among breast cancer outpatients compared with the general population. Altern Ther Health Med 5:71–76
Metadata
Title
Complementary and alternative medicine use in breast cancer patients in Europe
Authors
Alexander Molassiotis
Julia A. Scott
Nora Kearney
Dorit Pud
Miriam Magri
Sarka Selvekerova
Ingrid Bruyns
Paz Fernadez-Ortega
Vassiliki Panteli
Anita Margulies
Gudbjorg Gudmundsdottir
Ljiljana Milovics
Gulten Ozden
Nurgun Platin
Elisabeth Patiraki
Publication date
01-03-2006
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 3/2006
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-005-0883-7

Other articles of this Issue 3/2006

Supportive Care in Cancer 3/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine